OnabotulinumtoxinA in chronic migraine: predictors of response. A prospective multicentre descriptive study

Autor: M. Huerta, Patricia Pozo-Rosich, Marta Torres-Ferrus, J. García-Alhama, N. Hernández-Beltrán, A. Gago, L.C. Álvaro, C. González-Oria, R. Belvís, M.J. Monzón, Clara Domínguez, M. Gallego, S. Santos, V. Medrano, Yago Leira, Rogelio Leira, G. Latorre, C. Jurado-Cobo
Rok vydání: 2017
Předmět:
Zdroj: European Journal of Neurology. 25:411-416
ISSN: 1468-1331
1351-5101
Popis: Background and purpose: OnabotulinumtoxinA is a treatment specifically approved for the prophylaxis of chronic migraine in adults. The aim of this study was to assess the effectiveness of OnabotulinumtoxinA in chronic migraine after 1 year of treatment in a real-life setting and to identify clinical predictors of outcome. Methods: We designed a prospective multicentre study performed in 13 hospitals in Spain. Patients underwent a complete medical history and examination. They were treated with OnabotulinumtoxinA every 12 weeks for 1 year. Data about outcome, adverse events, abortive medication use, emergency room use and disability were collected at 3 and 12 months. Results: A total of 725 subjects completed the study. At 12 months, 79.3% showed >50% reduction in number of headaches per month and 94.9% reported no adverse events. Unilaterality of pain, fewer days of disability per month and milder headache at baseline were correlated with good outcome. Duration of disease
Databáze: OpenAIRE